JP2005289815A - External preparation for enhancing cell activity - Google Patents
External preparation for enhancing cell activity Download PDFInfo
- Publication number
- JP2005289815A JP2005289815A JP2002113217A JP2002113217A JP2005289815A JP 2005289815 A JP2005289815 A JP 2005289815A JP 2002113217 A JP2002113217 A JP 2002113217A JP 2002113217 A JP2002113217 A JP 2002113217A JP 2005289815 A JP2005289815 A JP 2005289815A
- Authority
- JP
- Japan
- Prior art keywords
- external preparation
- cell activity
- skin
- aqueous solution
- total weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000002708 enhancing effect Effects 0.000 title abstract description 6
- 150000004676 glycans Chemical class 0.000 claims abstract description 14
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 14
- 239000005017 polysaccharide Substances 0.000 claims abstract description 14
- 229920002000 Xyloglucan Polymers 0.000 claims abstract description 13
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 108010001062 polysaccharide-K Proteins 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- 229920002307 Dextran Polymers 0.000 claims abstract description 8
- 229920001491 Lentinan Polymers 0.000 claims abstract description 7
- 229940115286 lentinan Drugs 0.000 claims abstract description 7
- 239000001814 pectin Substances 0.000 claims abstract description 7
- 229920001277 pectin Polymers 0.000 claims abstract description 7
- 235000010987 pectin Nutrition 0.000 claims abstract description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 6
- 229920001218 Pullulan Polymers 0.000 claims abstract description 5
- 239000004373 Pullulan Substances 0.000 claims abstract description 5
- 235000019423 pullulan Nutrition 0.000 claims abstract description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 230000001737 promoting effect Effects 0.000 claims description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 15
- 230000001413 cellular effect Effects 0.000 abstract description 10
- 230000035876 healing Effects 0.000 abstract description 10
- 210000002850 nasal mucosa Anatomy 0.000 abstract description 10
- 210000000214 mouth Anatomy 0.000 abstract description 8
- 210000001519 tissue Anatomy 0.000 abstract description 7
- 208000003265 stomatitis Diseases 0.000 abstract description 6
- 229920001543 Laminarin Polymers 0.000 abstract description 2
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 abstract description 2
- 210000004761 scalp Anatomy 0.000 abstract description 2
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 15
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 13
- 210000004927 skin cell Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000036039 immunity Effects 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- -1 sodium chloride Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 3
- 201000004647 tinea pedis Diseases 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000003676 hair preparation Substances 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QMDPAEWMWMZYOS-YWSMWOPSSA-N (2R,3S,4S,5R)-2,3,4,5,6-pentahydroxy-1-[(3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]hexan-1-one Chemical compound C[C@@H]1OC([C@@H](O)[C@H](O)[C@@H]1O)C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO QMDPAEWMWMZYOS-YWSMWOPSSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
【０００１】
【発明の属する技術分野】
本発明は、細胞活性促進外用剤に係り、主に花粉症や口内炎などの諸疾患に優れた改善効果を有すると共に、細胞に対しての電解質バランス、浸透圧バランスを応用して細胞を活性化し、膚細胞の細胞機能低下による諸疾患を改善する細胞活性促進外用剤に関するものである。
【０００２】
【従来の技術】
従来、塩化ナトリウム等の無機塩や、ブドウ糖等の天然糖、或いは血漿などは、夫々化粧品や医薬外用剤の配合剤として広く使用されている。例えば、塩化ナトリウム等を含んだ肌を和らげるクリームに関するものが、U.S.P.3574854号公報に記載され、一方、ミネラル塩類を含んだ皮膚を衛生的にする出願は、西独国特許出願公開第3327840号明細書に見られる。更に、グルコース等を混合した肌を滑らかにする糖の成分に関する出願として、U.S.P.3859436号公報に記載され、また、シェービング用デキストラン水溶液に関する出願は、U.S.P.3777597号公報に記載されている。
【０００３】
ところが、これら従来の外用剤では、皮膚殺菌及び皮膚の保護の目的が達せられても、皮膚の毛細血管の循環及び機能低下による皮膚疾患、すなわち色素沈着症、水虫、インキン、タムシ、ワキガ、脱毛症、フケ、かゆみ等の皮膚細胞分裂機能低下による諸疾患を改善することは困難であった。
【０００４】
そこで、当発明者は、皮膚細胞を活性化し、皮膚細胞の細胞機能低下による諸疾患を改善するものとして、皮膚細胞間質液と同様な環境を皮膚表面に作り出し、電解質バランス、浸透圧バランスを応用することで、皮膚の表面からも障害細胞の正常化を促進することが可能になった水性皮膚及び毛髪化粧料を発明している（特許第1597430号）。
【０００５】
そして、この水性皮膚及び毛髪化粧料にあっては、シミ、赤ら顔の場合は皮下細胞を刺激、分裂させ、治癒に導びき、また、頭皮、ワキガ等に対しては浸透圧作用により毛母細胞を刺激し、発毛及び脱臭作用を促進させる効果が見られた。すなわち、この水性皮膚及び毛髪化粧料では、脱毛症に対する治癒率が83％、色素沈着症に対する治癒率が95％、赤ら顔の治療率が53％といった効能結果が得られている。
【０００６】
ところが、これらの効能は、主に皮膚や毛髪に対して顕著な効果が認められたものであり、当発明者は、皮膚細胞等の活性化の如く、副作用なしで粘膜細胞をも活性化させ得るなら、口腔の粘膜疾患による口内炎や、鼻粘膜の障害による花粉症などの疾患にもその効能が及ぶ可能性に着眼した。
【０００７】
そこで当発明者は、更に、口腔や鼻粘膜用の外用剤として使用しても副作用の虞が全く無く、例えば、口内炎や花粉症などといった、より広範囲な細胞レベルにおける諸疾患にも適用することが可能な細胞活性促進外用剤を発明している（特許第2681527号）。この細胞活性促進外用剤は、デキストラン等の多糖類やブドウ糖、ムタン、レンチナンなどを添加したものである。この細胞活性促進外用剤では、口内炎に対する治癒率が100％、花粉症に対する治癒率が100％といった優れた結果が得られている。
【０００８】
【発明が解決しようとする課題】
ところが、先の細胞活性促進外用剤において示された花粉症に対する治癒率は、当時、対象人数を４０人とした場合に示されたものであり、その後、花粉症の患者が急増するにつれて、花粉症の治癒率が次第に低下する傾向にあった。すなわち、前回（平成2年）の効能試験において、花粉症で100％を示していた有効率は、その後、十数年を経過した今日、発症率の爆発的増加に反比例するように、有効率が急激に下降していることが分かった。そもそも、花粉症が発症する原因は未だ明らかになっていないが、個人的な要因が口腔や鼻粘膜等の細胞レベルに何等かの影響を与えて発症を誘発すると考えられている。したがって、口腔や鼻粘膜等の免疫力や治癒力を高め、細胞組織を健康な状態に保つことで、個々の要因による悪影響を防止することが可能になり、急増する花粉症の発症を抑止すると共に、治癒効果も生じると考えられる。
【０００９】
そこで本発明は、先に発明した細胞活性促進外用剤に更に改良を加えることで、口腔や鼻粘膜等の細胞組織の免疫力や治癒力を高め、しかも副作用の虞が全く無く、花粉症や口内炎は勿論、皮膚や頭皮等の広範囲な細胞レベルにおける諸疾患にも適用することが可能な細胞活性促進外用剤の提供を目的とする。
【００１０】
【課題を解決するための手段】
上述の目的を達成すべく本発明の第１の手段は、多糖類を水溶液中に溶解した細胞活性促進外用剤であって、全体の重量比で、１〜50％のキシログルカンと、１〜50％のラミラナンと、１〜50％のクレスチンとを添加したことにある。
【００１１】
第２の手段は、多糖類を溶解した水溶液中に、全体の重量比で、１〜50％のペクチンと、１〜30％のデキストランと、１〜30％のブドウ糖と、１〜40％のプルランと、１〜30％のレンチナンと、１〜50％のトレハロースとを含有する。
【００１２】
第３の手段は、多糖類を溶解した水溶液中に、全体の重量比で、0.1〜1％の塩化ナトリウムと、0.1〜1％の塩化カルシウムと、0.1〜1％の塩化カリウムとを添加したことを課題解消のための手段とする。
【００１３】
人間の皮膚における病変である炎症、色素沈着、脱毛症等の各種症状の原因は、紫外線、化学物質等の種々の因子が関連したものとなっており、その細胞レベルでの変化が限られているその根本は、細胞内小器官の一つであるミトコンドリアの膜や細胞膜の障害といえるものである。つまり、ミトコンドリアの膜の障害によって細胞内呼吸の阻害が生じ、これによって、細胞の活動源たるATP（アデノシン３リン酸）の産生が低下する。このようなATPの不足によって細胞膜の能動輸送の機能が低下し、細胞と間質液との間において物質の輸送能力の低下が起る。すると、細胞内におけるグルコース等の栄奏物質の不足を生じさせ、ひいてはATPの酸性の低下につながるといった悪循環をなすものである。
【００１４】
以上のような細胞レベルでの変化を生じさせる原因は多様なものがあり、特に、口腔や鼻粘膜等の細胞においては、浸透圧作用で細胞問質液を引き上げることで、疾患部分の細胞を活性化することができる。更に、キシログルカンと、ラミラナンと、クレスチンとを添加することにより、口腔や鼻粘膜等の細胞組織の免疫力や治癒力を高めることが可能になると考えられる。
【００１５】
【発明の実施の形態】
本発明の基本的な配合は、多糖類を溶解した水溶液中に、全体の重量比で、１〜50％のキシログルカンと、１〜50％のラミラナンと、１〜50％のクレスチンとを添加するものである。
【００１６】
キシログルカンは、伸長・肥大している植物細胞の壁（一次壁）に普遍的に存在する構成糖鎖である。植物種特異性は、キシロース残基にガラクトースまたはフコシル−ガラクトースが結合することによって生じる。このガラクトース残基及びフコース残基にはそれぞれレクチンが結合できるが、これら分岐糖鎖の機能は分かっていない。植物細胞の成長は、細胞の持っている浸透圧に由来する吸水現象によって生じ、吸水力は、細胞壁のゆるみによる壁圧の減少によって生じる。この細胞壁のゆるみは、未だ解明されていないが、細胞伸長は常にキシログルカンの分解と可溶化を伴って生じており、細胞の生理活性をつかさどる多糖類のひとつとして注目されている。
【００１７】
ラミラナンは、炭水化物の一でβグルカンのラミラナンとして分類される。椎茸をはじめとした茸類や昆布などの海草類に含まれるもので、免疫力を高める効果がある。単独では吸収され難く、たんぱく質と一緒に摂取するとよいことが知られている。
【００１８】
クレスチンは、ヒト癌細胞のＨＬＡクラスＩ抗原の発現を増強する免疫治療医薬品として使用されるもので、かわらたけ菌糸体より抽出される。このクレスチンは、胃癌、結腸・直腸癌、小細胞肺癌等の腫瘍性疾患に免疫治療作用が認められている。
【００１９】
発明者は、数多くの多糖類の中から、外用剤に適した成分を研究した結果、これらのキシログルカン、ラミラナン、クレスチンを組合せることで、口腔や鼻粘膜等の細胞組織の免疫力や治癒力を高める外用剤を調製したものである。
【００２０】
これらの多糖類を溶解した水溶液中には、予め、全体の重量比で、１〜50％のペクチンと、１〜30％のデキストランと、１〜30％のブドウ糖と、１〜30％のレンチナンと、１〜50％のトレハロースとを含有せしめてある。
【００２１】
ペクチンは、植物の細胞壁の構成成分としてセルロース等、他の成分と結合することで植物細胞をつなぎ合わせる働きをしている。ゲル化作用を持つ成分であり、本発明外用剤の添加剤として好適である。
【００２２】
また、多糖類を溶解した水溶液中に、塩化ナトリウムと、塩化カルシウムと、塩化カリウムとを添加している。塩化ナトリウムの配合量は、皮膚に対する浸透圧バランス、電解質バランスの有効性、すなわち、皮膚細胞を活性化できるよう、全体の重量比で0.1〜1％とし、同様に、塩化カルシウムと、塩化カリウムにおいても0.1〜1％の各成分を水相成分に溶解する。
【００２３】
【実施例】
次に、処方例及び薬理試験例を挙げて本発明の外用剤を具体的に説明する。
【００２４】
−処方例１−
デキストラン １８
ブドウ糖 １０
サイクロデキストリン ２
トレハロース ３
プルラン ７
レンチナン ７
ラミナラン ２
クレスチン １
ペクチン ３
キシログルカン １
塩化ナトリウム ０．９
塩化カルシウム ０．３
塩化カリウム ０．３
精製水 ４４．５
計 重量比（％） １００
【００２５】
水相成分（精製水）は、純水のみで製造するノンオイルのもので、化粧品等、通常の外用剤の製造時に使用されている水溶性石油系の界面活性剤等は一切含有しない。そして、これらの各成分と水相成分との混合に際しては、各成分の溶解を完全にするために、50〜100℃の温度で実施する。
【００２６】
次に、処方例１の効果を表１に示す。
【００２７】
【表１】
表１は、処方例１の薬理試験による結果を示すものである。このときの有効性とは、本発明外用剤の使用により、変化なしを０ポイント、治癒に向う変化があったものを１ポイント、効果が確認されたものを２ポイントとした各人の合計点を出し、次の式で算出したものである。尚、今回の試験は、特に花粉症の治癒効果を確認するために、疾患者１００人を対象として有効率を算出した。
【００２９】
【数１】
この結果、１００人の花粉症を対象にしても98％の有効率が得られた。前回（平成2年）の試験において、花粉症で100％を示していた有効率は、その後、十数年を経過した今日、発症率の爆発的増加に反比例するように、有効率が急激に下降していたが、本発明によって98％の有効率を維持できるようになっていることは特筆すべき効果であるといえる。また、600症例中、ただの一例も副作用が認められず、しかも、男性型脱毛症やニキビ、水虫、脂漏性皮膚炎など、治癒改善が困難な疾患に対しても極めて有効である。
【００３１】
更に、処方例２の混合比からなる本発明外用剤を調合した。
【００３２】
−処方例２−
デキストラン ４
ブドウ糖 ３
サイクロデキストリン ２
トレハロース ３
プルラン ３
レンチナン ３
ラミナラン ２
クレスチン １
ペクチン ３
キシログルカン ５０
塩化ナトリウム ０．４
塩化カルシウム ０．３
塩化カリウム ０．３
精製水 ２５
計 重量比（％） １００
【００３３】
この結果、処方例２以上にキシログルカンの濃度を上げると、溶解後分離するようになってしまい、処方として不適当になった。また、キシログルカンの他、ラミナラン、クレスチンのいずれにおいても有効性が認められるのは少なくとも夫々１％以上の濃度が必要であり、また夫々の濃度が５０％を超えると処方できなくなることが分かった。
【００３４】
【発明の効果】
本発明によると、全体の重量比で、１〜50％のキシログルカンと、１〜50％のラミラナンと、１〜50％のクレスチンとの各成分を、水相成分に添加したことにより、口腔や鼻粘膜等の細胞組織の免疫力や治癒力を高めることが可能になり、花粉症などの個人的要因が作用する疾患でも有効な治癒効果が得られる。
【００３５】
また、細胞組織の免疫力や治癒力を高めながら皮膚細胞間質液と同様な環境を作り出すことができるので、ミトコンドリアの膜の障害によって生じる、細胞内呼吸の阻害や、細胞の活動源たるATP（アデノシン３リン酸）の産生の低下を防止することができ、電解質バランス、浸透圧バランスを保ち、皮膚細胞や粘膜細胞の表層からも障害細胞の正常化を促進することが可能になり、男性型脱毛症やニキビ、水虫、脂漏性皮膚炎など、治癒改善が困難な疾患に対しても極めて有効であり、本発明の意義は極めて大きく、人類に大きく貢献するものである。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an agent for promoting cell activity, mainly having an improvement effect on various diseases such as hay fever and stomatitis, and activating cells by applying electrolyte balance and osmotic pressure balance to the cells. The present invention relates to an agent for promoting cell activity that improves various diseases caused by a decrease in skin cell function.
[0002]
[Prior art]
Conventionally, inorganic salts such as sodium chloride, natural sugars such as glucose, or plasma have been widely used as a formulation for cosmetics and pharmaceutical external preparations. For example, a cream relating to a soothing skin containing sodium chloride or the like is described in USP3574854, while an application for sanitizing skin containing mineral salts is disclosed in West German Patent Application No. 3327840. It can be seen. Further, an application relating to a sugar component that smoothes skin mixed with glucose or the like is described in USP3859436, and an application relating to a dextran aqueous solution for shaving is described in USP3777597.
[0003]
However, in these conventional external preparations, even if the purpose of skin sterilization and protection of the skin is achieved, skin diseases caused by the circulatory and functional deterioration of the skin capillaries, i.e., pigmentation, athlete's foot, insect, worm, hair loss It has been difficult to ameliorate various diseases caused by reduced skin cell division function such as symptom, dandruff and itching.
[0004]
Therefore, the present inventor has created an environment similar to the skin cell interstitial fluid on the skin surface to activate the skin cells and improve various diseases caused by the decreased cell functions of the skin cells, and to maintain the electrolyte balance and osmotic pressure balance. By applying it, the inventors have invented aqueous skin and hair cosmetics that can promote normalization of damaged cells from the surface of the skin (Japanese Patent No. 1597430).
[0005]
In the case of this aqueous skin and hair cosmetic, in the case of spots and red face, the subcutaneous cells are stimulated and divided, leading to healing. The effect of stimulating hair and promoting hair growth and deodorizing action was observed. In other words, the aqueous skin and hair cosmetics have obtained efficacy results such as a cure rate for alopecia of 83%, a cure rate for pigmentation of 95%, and a cure rate of red face of 53%.
[0006]
However, these effects are recognized mainly for skin and hair, and the present inventors activate mucosal cells without side effects such as activation of skin cells and the like. If possible, we focused on the possibility that the effect could also be applied to diseases such as stomatitis due to oral mucosal disease and hay fever due to damage to the nasal mucosa.
[0007]
Therefore, the present inventor further has no fear of side effects even when used as an external preparation for oral cavity or nasal mucosa, and can be applied to various diseases in a wider range of cells such as stomatitis and hay fever. Has invented an external preparation for promoting cell activity (Japanese Patent No. 2681527). This external preparation for promoting cell activity is obtained by adding polysaccharides such as dextran, glucose, mutan, lentinan and the like. With this cell activity promoting external preparation, excellent results have been obtained, such as a cure rate for stomatitis of 100% and a cure rate for hay fever of 100%.
[0008]
[Problems to be solved by the invention]
However, the cure rate for hay fever shown in the above-mentioned external preparation for promoting cell activity was shown at the time when the number of subjects was 40, and as the number of patients with hay fever increased rapidly thereafter, pollen The cure rate of the disease tended to decrease gradually. In other words, the effectiveness rate, which showed 100% in hay fever in the previous efficacy test (Heisei 2), is an effective rate so that it is inversely proportional to the explosive increase in the incidence rate after 10 years. It has been found that is falling rapidly. In the first place, the cause of the development of hay fever has not yet been clarified, but it is thought that personal factors have some influence on the cellular level of the oral cavity and nasal mucosa to induce the onset. Therefore, by improving the immunity and healing power of the oral cavity, nasal mucosa, etc. and keeping the cellular tissue in a healthy state, it becomes possible to prevent adverse effects due to individual factors and suppress the onset of rapidly increasing hay fever. At the same time, it is considered that a healing effect also occurs.
[0009]
Therefore, the present invention further improves the immunity and healing power of cell tissues such as the oral cavity and the nasal mucosa by adding further improvements to the cell activity promoting external preparation previously invented, and there is no risk of side effects. It is an object of the present invention to provide an external preparation for promoting cell activity that can be applied not only to stomatitis but also to various diseases in a wide range of cells such as skin and scalp.
[0010]
[Means for Solving the Problems]
In order to achieve the above-mentioned object, the first means of the present invention is a cell activity promoting external preparation in which a polysaccharide is dissolved in an aqueous solution, and 1 to 50% xyloglucan in a total weight ratio, The addition of 50% lamiranan and 1-50% krestin.
[0011]
The second means is that, in an aqueous solution in which polysaccharides are dissolved, 1 to 50% pectin, 1 to 30% dextran, 1 to 30% glucose, and 1 to 40% by weight of the total weight ratio. Contains pullulan, 1-30% lentinan, and 1-50% trehalose.
[0012]
The third means is that 0.1 to 1% sodium chloride, 0.1 to 1% calcium chloride, and 0.1 to 1% potassium chloride are added to the aqueous solution in which the polysaccharide is dissolved in the total weight ratio. This is a means for solving the problem.
[0013]
Causes of various symptoms such as inflammation, pigmentation, and alopecia that are lesions in human skin are related to various factors such as ultraviolet rays and chemical substances, and their changes at the cellular level are limited. The root of this is a disorder of the mitochondrial membrane and cell membrane, one of the organelles. In other words, damage to the mitochondrial membrane results in inhibition of intracellular respiration, thereby reducing the production of ATP (adenosine triphosphate), which is the source of cellular activity. Such a deficiency in ATP reduces the function of active transport of the cell membrane, leading to a decrease in the ability to transport substances between cells and interstitial fluid. This causes a vicious circle in which intracellular deprivation substances such as glucose are deficient, leading to a decrease in the acidity of ATP.
[0014]
There are a variety of causes that cause changes at the cellular level as described above. In particular, in cells such as the oral cavity and nasal mucosa, the cells in the diseased part are removed by raising the cell interstitial fluid by osmotic pressure action. Can be activated. Furthermore, it is considered that by adding xyloglucan, lamiranan and krestin, the immunity and healing power of cell tissues such as the oral cavity and nasal mucosa can be enhanced.
[0015]
DETAILED DESCRIPTION OF THE INVENTION
The basic composition of the present invention is the addition of 1 to 50% xyloglucan, 1 to 50% lamiranan and 1 to 50% krestin in a total weight ratio in an aqueous solution in which a polysaccharide is dissolved. To do.
[0016]
Xyloglucan is a constituent sugar chain that exists universally on the wall (primary wall) of plant cells that are elongated and enlarged. Plant species specificity arises from the binding of galactose or fucosyl-galactose to xylose residues. Lectins can bind to these galactose and fucose residues, but the functions of these branched sugar chains are not known. Plant cell growth is caused by a water absorption phenomenon derived from the osmotic pressure of the cell, and water absorption is caused by a decrease in wall pressure due to loosening of the cell wall. This loosening of the cell wall has not yet been elucidated, but cell elongation is always accompanied by degradation and solubilization of xyloglucan, and is attracting attention as one of the polysaccharides that control the physiological activity of cells.
[0017]
Ramilanan is one of the carbohydrates and is classified as a β-glucan lamiranan. It is contained in seaweeds such as shiitake mushrooms and kelp and has the effect of enhancing immunity. It is known that it is difficult to absorb by itself and should be taken with protein.
[0018]
Krestin is used as an immunotherapeutic drug that enhances the expression of HLA class I antigens in human cancer cells, and is extracted from chopped mycelium. This krestin has been shown to have an immunotherapeutic effect on neoplastic diseases such as gastric cancer, colorectal cancer, and small cell lung cancer.
[0019]
As a result of researching ingredients suitable for external preparations from among many polysaccharides, the inventor has combined these xyloglucans, lamiranans, and krestins to immunize and heal cellular tissues such as the oral cavity and nasal mucosa. This is a preparation for external use that increases strength.
[0020]
In an aqueous solution in which these polysaccharides are dissolved, 1 to 50% pectin, 1 to 30% dextran, 1 to 30% glucose, and 1 to 30% lentinan in a total weight ratio in advance. And 1 to 50% trehalose.
[0021]
Pectin functions to connect plant cells by binding to other components such as cellulose as a component of plant cell walls. It is a component having a gelling action and is suitable as an additive for the external preparation of the present invention.
[0022]
Moreover, sodium chloride, calcium chloride, and potassium chloride are added to the aqueous solution in which the polysaccharide is dissolved. The amount of sodium chloride is 0.1 to 1% in the total weight ratio so that the osmotic pressure balance and the electrolyte balance on the skin, that is, the skin cells can be activated. Similarly, in calcium chloride and potassium chloride Also, 0.1 to 1% of each component is dissolved in the aqueous phase component.
[0023]
【Example】
Next, the preparation for external use of the present invention will be specifically described with reference to formulation examples and pharmacological test examples.
[0024]
-Prescription Example 1-
Dextran 18
Glucose 10
Cyclodextrin 2
Trehalose 3
Pullulan 7
Lentinan 7
Lamina Run 2
Krestin 1
Pectin 3
Xyloglucan 1
Sodium chloride 0.9
Calcium chloride 0.3
Potassium chloride 0.3
Purified water 44.5
Total weight ratio (%) 100
[0025]
The water phase component (purified water) is a non-oil produced only with pure water, and does not contain any water-soluble petroleum-based surfactants used at the time of producing ordinary external preparations such as cosmetics. And when mixing each of these components and an aqueous phase component, in order to complete melt | dissolution of each component, it implements at the temperature of 50-100 degreeC.
[0026]
Next, Table 1 shows the effects of Formulation Example 1.
[0027]
[Table 1]
Table 1 shows the results of the pharmacological test of Formulation Example 1. The effectiveness at this time is the total score for each person, with 0 points indicating no change, 1 point indicating a change in healing, and 2 points indicating a confirmed effect due to the use of the external preparation of the present invention. And calculated by the following formula. In addition, in this test, in order to confirm the curative effect of hay fever in particular, the effective rate was calculated for 100 patients with disease.
[0029]
[Expression 1]
As a result, an effective rate of 98% was obtained even for 100 people with hay fever. The effectiveness rate, which showed 100% in hay fever in the previous study (Heisei 2), has increased sharply so that it is inversely proportional to the explosive increase in the incidence rate after 10 years. Although it was decreasing, it can be said that it is a remarkable effect that the effective rate of 98% can be maintained by the present invention. In addition, only one of the 600 cases has no side effects, and is extremely effective for diseases that are difficult to improve, such as androgenetic alopecia, acne, athlete's foot, and seborrheic dermatitis.
[0031]
Furthermore, this invention external preparation which consists of the mixing ratio of the formulation example 2 was prepared.
[0032]
-Prescription Example 2-
Dextran 4
Glucose 3
Cyclodextrin 2
Trehalose 3
Pullulan 3
Lentinan 3
Lamina Run 2
Krestin 1
Pectin 3
Xyloglucan 50
Sodium chloride 0.4
Calcium chloride 0.3
Potassium chloride 0.3
Purified water 25
Total weight ratio (%) 100
[0033]
As a result, when the concentration of xyloglucan was increased to more than that in Formulation Example 2, it became separated after dissolution, making it unsuitable as a formulation. In addition to xyloglucan, it has been found that at least 1% or more of each concentration is required to be effective in both laminaran and krestin, and it is impossible to prescribe when each concentration exceeds 50%. .
[0034]
【The invention's effect】
According to the present invention, by adding each component of 1 to 50% xyloglucan, 1 to 50% lamiranan and 1 to 50% krestin in the total weight ratio to the aqueous phase component, It is possible to enhance the immunity and healing power of cellular tissues such as nasal mucosa and the like, and an effective healing effect can be obtained even in diseases in which individual factors such as pollinosis act.
[0035]
In addition, it can create an environment similar to that of skin cell interstitial fluid while enhancing the immunity and healing power of cellular tissues, so that inhibition of intracellular respiration caused by mitochondrial membrane damage and ATP as the source of cellular activity (Adenosine triphosphate) production can be prevented, electrolyte balance and osmotic pressure balance can be maintained, and normalization of damaged cells can be promoted from the surface layer of skin cells and mucosal cells. The present invention is extremely effective even for diseases that are difficult to improve, such as type alopecia, acne, athlete's foot, and seborrheic dermatitis, and the significance of the present invention is extremely great and greatly contributes to mankind.
Claims (3)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002113217A JP3885204B2 (en) | 2002-04-16 | 2002-04-16 | External agent for promoting cell activity |
| TW092103549A TWI254639B (en) | 2002-04-16 | 2003-02-20 | External preparations for enhancing cell activity |
| PCT/JP2003/002536 WO2003086421A1 (en) | 2002-04-16 | 2003-03-05 | External preparations for enhancing cell activity |
| AU2003213370A AU2003213370A1 (en) | 2002-04-16 | 2003-03-05 | External preparations for enhancing cell activity |
| CNB031088236A CN1240392C (en) | 2002-04-16 | 2003-03-26 | Agent for promoting cell activation for external use |
| HK04102877A HK1060048A1 (en) | 2002-04-16 | 2004-04-23 | Agent for external application for enhancing cell activation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002113217A JP3885204B2 (en) | 2002-04-16 | 2002-04-16 | External agent for promoting cell activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005289815A true JP2005289815A (en) | 2005-10-20 |
| JP3885204B2 JP3885204B2 (en) | 2007-02-21 |
Family
ID=29243346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002113217A Expired - Lifetime JP3885204B2 (en) | 2002-04-16 | 2002-04-16 | External agent for promoting cell activity |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP3885204B2 (en) |
| CN (1) | CN1240392C (en) |
| AU (1) | AU2003213370A1 (en) |
| HK (1) | HK1060048A1 (en) |
| TW (1) | TWI254639B (en) |
| WO (1) | WO2003086421A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005053841A (en) * | 2003-08-05 | 2005-03-03 | Kyouto Biomedical Science:Kk | Skin care preparation for external use |
| DE102007052380A1 (en) * | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolyte-containing preparations for use in dry mucous membranes |
| JP2012012328A (en) * | 2010-06-30 | 2012-01-19 | Dsp Gokyo Food & Chemical Co Ltd | Xyloglucan-cation complex and stabilized composition containing the same |
| JP2015218137A (en) * | 2014-05-16 | 2015-12-07 | 株式会社Cac | IgE inhibitor |
| FR3064473A1 (en) * | 2017-04-03 | 2018-10-05 | Basf Beauty Care Solutions France Sas | PROTECTIVE INGREDIENT FOR THE BALANCE OF THE MICROBIAL SKIN FLORA AND / OR MUCOSAL |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1285382C (en) * | 2004-12-20 | 2006-11-22 | 凌沛学 | Transmission system of drug for nasal cavity of containing trehalose and byaluronic acid, and preparation method |
| CN103239571B (en) * | 2013-05-26 | 2014-09-03 | 广州市云桥生物科技有限公司 | Chinese medicine effective part composition for treating alopecia areata and preparation method thereof |
| WO2017058175A1 (en) * | 2015-09-29 | 2017-04-06 | Kimberly-Clark Worldwide, Inc. | Synergistic composition for maintenance of healthy balance of microflora |
| BE1027425B1 (en) * | 2019-07-01 | 2021-02-08 | Aquilon Pharmaceuticals | INHALABLE COMPOSITION INCLUDING CYCLODEXTRIN FOR USE IN THE TREATMENT OF NASAL INFLAMMATIONS |
| DE212021000176U1 (en) * | 2021-10-16 | 2022-01-04 | Nantong Jujiu New Material Science and Technology Co., Ltd. | Peripheral blood mononuclear cell culture dish coated with Yunzhi polysaccharide |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03204804A (en) * | 1989-12-28 | 1991-09-06 | Mitsui Toatsu Chem Inc | Skin cosmetic |
| JP2681527B2 (en) * | 1990-02-15 | 1997-11-26 | ジャパンファインケミカル株式会社 | Topical for promoting cell activity |
| DE19710368A1 (en) * | 1997-03-13 | 1998-09-17 | Henkel Kgaa | Use of water-soluble beta-glucans as active ingredients for the production of therapeutic agents for skin treatment |
| JP2002275046A (en) * | 2001-03-23 | 2002-09-25 | Kanebo Ltd | Agent for enhancing barrier against penetration through epidermis, and skin care composition |
-
2002
- 2002-04-16 JP JP2002113217A patent/JP3885204B2/en not_active Expired - Lifetime
-
2003
- 2003-02-20 TW TW092103549A patent/TWI254639B/en not_active IP Right Cessation
- 2003-03-05 AU AU2003213370A patent/AU2003213370A1/en not_active Abandoned
- 2003-03-05 WO PCT/JP2003/002536 patent/WO2003086421A1/en active Application Filing
- 2003-03-26 CN CNB031088236A patent/CN1240392C/en not_active Expired - Fee Related
-
2004
- 2004-04-23 HK HK04102877A patent/HK1060048A1/en not_active IP Right Cessation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005053841A (en) * | 2003-08-05 | 2005-03-03 | Kyouto Biomedical Science:Kk | Skin care preparation for external use |
| DE102007052380A1 (en) * | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolyte-containing preparations for use in dry mucous membranes |
| JP2012012328A (en) * | 2010-06-30 | 2012-01-19 | Dsp Gokyo Food & Chemical Co Ltd | Xyloglucan-cation complex and stabilized composition containing the same |
| JP2015218137A (en) * | 2014-05-16 | 2015-12-07 | 株式会社Cac | IgE inhibitor |
| FR3064473A1 (en) * | 2017-04-03 | 2018-10-05 | Basf Beauty Care Solutions France Sas | PROTECTIVE INGREDIENT FOR THE BALANCE OF THE MICROBIAL SKIN FLORA AND / OR MUCOSAL |
| WO2018185408A1 (en) * | 2017-04-03 | 2018-10-11 | Basf Beauty Care Solutions France Sas | Protective ingredient for balancing the cutaneous and/or mucosal microbial flora |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200407154A (en) | 2004-05-16 |
| CN1240392C (en) | 2006-02-08 |
| AU2003213370A1 (en) | 2003-10-27 |
| TWI254639B (en) | 2006-05-11 |
| HK1060048A1 (en) | 2004-07-30 |
| WO2003086421A1 (en) | 2003-10-23 |
| JP3885204B2 (en) | 2007-02-21 |
| CN1451389A (en) | 2003-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2681527B2 (en) | Topical for promoting cell activity | |
| US9629856B2 (en) | Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds | |
| EP1386613A1 (en) | Compositions for preparing external carbon dioxide agents | |
| JP3885204B2 (en) | External agent for promoting cell activity | |
| Neena et al. | An ancient herb aloevera in dentistry: A review | |
| TWI278318B (en) | External preparations for treating dermatitis | |
| AU705996B2 (en) | External therapeutic composition for dermatitis | |
| JP3890563B2 (en) | Permanent wave agent | |
| CN103463627A (en) | Oral care composition containing heat-resistant superoxide dismutase and growth factors | |
| JP3890564B2 (en) | Oxidative hair dye | |
| JPH0212443B2 (en) | ||
| JP3503880B2 (en) | Oral composition | |
| JP2766811B2 (en) | Aqueous skin external preparation | |
| JPH10287550A (en) | Preparation for external use for skin | |
| KR20120001872A (en) | Cosmetic composition containing spring water and pueraria lobata root extract for sensitive skin and its producing method | |
| EP1296667B1 (en) | Compounds for preventing and/or treating urticaria | |
| RU2092156C1 (en) | Solution for skin repair stimulation | |
| KR20180107334A (en) | Compositions for improving dry skin comprising swiftlet´s nest extract and fucoidan | |
| KR20090099112A (en) | Functional toothpaste including nano silver | |
| BR102016015826A2 (en) | ORAL MOISTURE SOLUTION BASED ON CELLULOSE AND PROPOLIS DERIVATIVES AND THEIR OBTAINING PROCESS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060502 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060711 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060810 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060919 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061024 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061110 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 3885204 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101201 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111201 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121201 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131201 Year of fee payment: 7 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |